The observation that anti-EMP2 IgG1 slowed tumor growth in breast cancer xenografts without detectable systemic toxicity indicates its immunotherapeutic value for the treatment of tumors with positive EMP2 expression [50]. This evidence concerns the gene EMP2 and breast cancer.